other material
confidence high
sentiment positive
materiality 0.80
Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease
Gain Therapeutics, Inc.
- GT-02287 safe and well-tolerated after 90 days; no serious adverse events.
- Transient liver enzyme increases normalized with ongoing dosing.
- Mean UPDRS Part II and III scores improved at Day 90, suggesting disease-slowing effect.
- Plasma PK consistent across 14 participants, within therapeutic range.
- DMC recommended continuation; Australian authorities approved 12-month extension.